Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Nuvalent's Neladalkib Shows 44% Response Rate Across 14 Advanced ALK-Positive Solid Tumors Beyond NSCLC; Phase 2 ALKOVE-1 Trial Enrollment Ongoing Globally

Author: Benzinga Newsdesk | October 20, 2025 03:14am

Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors
Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors beyond NSCLC in a Phase 2 cohort of the ALKOVE-1 trial

Posted In: NUVL